A whole-animal platform to advance a clinical kinase inhibitor into new disease space-Reference-Cited by-同舟云学术

A whole-animal platform to advance a clinical kinase inhibitor into new disease space

Published:2018-01-22 Issue:3 Volume:14 Page:291-298
ISSN:1552-4450
Container-title:Nature Chemical Biology
language:en
Short-container-title:Nat Chem Biol

Author:

Sonoshita Masahiro,Scopton Alex P,Ung Peter M U,Murray Matthew A,Silber Lisa,Maldonado Andres Y,Real Alexander,Schlessinger Avner,Cagan Ross L,Dar Arvin C

Publisher

Springer Science and Business Media LLC

Subject

Cell Biology,Molecular Biology

Link

http://www.nature.com/articles/nchembio.2556.pdf

Reference58 articles.

1. Druker, B.J. et al. Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia. N. Engl. J. Med. 344, 1031–1037 (2001).

2. Flaherty, K.T. et al. Inhibition of mutated, activated BRAF in metastatic melanoma. N. Engl. J. Med. 363, 809–819 (2010).

3. Hollingsworth, S.J. Precision medicine in oncology drug development: a pharma perspective. Drug Discov. Today 20, 1455–1463 (2015).

4. Kandoth, C. et al. Mutational landscape and significance across 12 major cancer types. Nature 502, 333–339 (2013).

5. Lawrence, M.S. et al. Discovery and saturation analysis of cancer genes across 21 tumour types. Nature 505, 495–501 (2014).

Cited by 55 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Functional exploration of copy number alterations in a Drosophila model of triple-negative breast cancer;Disease Models & Mechanisms;2024-07-01

2. Flow zoometry ofDrosophila;2024-04-05

3. Concurrent targeting of GSK3 and MEK as a therapeutic strategy to treat pancreatic ductal adenocarcinoma;Cancer Science;2024-02-06

4. Polyploid Cancer Cell Models in Drosophila;Genes;2024-01-14

5. WNTinib is a multi-kinase inhibitor with specificity against β-catenin mutant hepatocellular carcinoma;Nature Cancer;2023-08-03